Avid Bioservices Inc (CDMO)

[pphmtoolong]

After two months of reviewing the 2nd Line NSCLC trial processes at the most basic level, Peregrine managment publicly stated they expect to be able to present data form this trial to the FDA to support approval of a pivotal trial. Until I hear otherwise from the people who have access to the review information, speculation here or anywhere else is not going to change my expectations that the trial data will be good enough to achieve its purposes - inspire a partner, convince the FDA to OK a Phase III. Obviously, this is not a lock, but it's much more reliable than speculation from those who do not have access to the trial data review process. Simple enough.

Paul